PROTEOMICS OF TOLL-LIKE RECEPTOR 2 & INTRACELLULAR FACTOR XIIIA IN PLATELETS
Toll 样受体 2 的蛋白质组学
基本信息
- 批准号:7602018
- 负责人:
- 金额:$ 0.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-08-03 至 2008-05-31
- 项目状态:已结题
- 来源:
- 关键词:Alpha GranuleAntibodiesArterial Fatty StreakAtherosclerosisBlood PlateletsComputer Retrieval of Information on Scientific Projects DatabaseCytoplasmic GranulesCytoskeletal ProteinsDNA Sequence RearrangementFundingGelGrantHemostatic functionImmuneImmune responseImmunoprecipitationInflammationInflammatoryInstitutionLinkMass Spectrum AnalysisMediatingMusPhagocytosisPlatelet ActivationPlayProcessProteinsProteomicsReportingResearchResearch PersonnelResourcesRestRoleSourceSurfaceTLR2 geneTalinToll-Like Receptor 2Toll-Like Receptor PathwayToll-like receptorsTrypsinUnited States National Institutes of HealthWestern Blottingcrosslinkfilaminmonocytenovelpathogen
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Beside hemostasis, platelets are known to play a role in immune responses and inflammatory processes. Interaction with pathogens involves pathogen recognition, release of granule-content, and cytoskeletal rearrangements in the platelet. Recently, we identified the expression of toll-like receptors (TLR) on the platelet surface, supporting a role for the platelet in innate immune responses. In addition, the TLR pathway links inflammation to atherosclerosis, as TLRs are expressed in atherosclerotic plaques and murine TLR2 stimulation causes enhanced atherosclerosis. Intracellular Factor XIIIA (FXIIIA) can crosslink platelet cytoskeletal proteins upon platelet activation. Relevant to the immune response, FXIIIA is required for cytoskeletal remodeling during monocyte phagocytosis, however, its role in platelet-mediated immune processes is unknown. We have applied a proteomics approach to search for TLR2- and FXIIIA-associated proteins in resting platelets. After immunoprecipitation (IP) of TLR2 and FXIIIA from platelet lysates followed by gel separation, protein bands were excised, digested with trypsin and analysed by mass spectrometry. Western blot analysis was applied to confirm the mass spectrometric results. We repeatedly immunoprecipitated FXIIIA directly with TLR2-specific antibodies, whereas the IP of FXIIIA pulled down a truncated form of TLR2, as identified by Western blot, that may correspond to the soluble form of TLR2. By mass spectrometry, we identified FXIIIA and FXIIIA-associated proteins: thrombospondin, filamin and talin. Importantly, talin has not been previously reported as FXIII-substrate or associated protein. Thrombospondin, a known FXIII substrate, is stored in platelet granules. A strong thrombospondin-band after FXIIIA-IP and a weak band after TLR2-IP suggests the partial presence of FXIIIA and soluble TLR2 in granules. Interestingly, FXIIIA appears to be associated with its substrates in the resting platelet. In conclusion, our results indicate the presence of known and novel FXIIIA-associated proteins in platelets and suggests a role for TLR2 and FXIIIA in platelet-dependent immune responses.
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
除了止血,我们还知道血小板在免疫反应和炎症过程中发挥作用。与病原体的相互作用涉及病原体的识别、颗粒内容物的释放和血小板中的细胞骨架重排。最近,我们发现了血小板表面Toll样受体的表达,支持血小板在先天免疫反应中的作用。此外,TLR途径将炎症与动脉粥样硬化联系起来,因为TLRs在动脉粥样硬化斑块中表达,而小鼠TLR2刺激导致动脉粥样硬化加剧。细胞内因子XIIIA(FXIIIA)可在血小板活化时使血小板细胞骨架蛋白发生交联。与免疫反应相关,FXIIIA是单核细胞吞噬过程中细胞骨架重塑所必需的,然而,它在血小板介导的免疫过程中的作用尚不清楚。我们应用蛋白质组学方法在静息血小板中寻找TLR2和FXIIIA相关蛋白。从血小板裂解液中免疫沉淀TLR2和FXIIIA后,凝胶分离,切下蛋白条带,胰酶消化后进行质谱分析。用Western印迹分析对质谱学结果进行验证。我们反复用TLR2特异性抗体直接免疫沉淀FXIIIA,而FXIIIA的IP经Western印迹鉴定,下调了TLR2的截短形式,可能与TLR2的可溶性形式相对应。通过质谱分析,我们鉴定了FXIIIA和FXIIIA相关蛋白:凝血酶原蛋白、细丝蛋白和Talin。重要的是,Talin之前还没有作为FXIII底物或相关蛋白的报道。凝血酶敏感蛋白是一种已知的FXIII底物,储存在血小板颗粒中。FXIIIA-IP后有一条较强的凝血酶原蛋白条带,TLR2-IP后有一条较弱的条带,提示FXIIIA和可溶性TLR2部分存在于颗粒中。有趣的是,FXIIIA似乎与其在静息血小板中的底物有关。总之,我们的结果表明在血小板中存在已知的和新的FXIIIA相关蛋白,并提示TLR2和FXIIIA在血小板依赖的免疫反应中发挥作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JANE E Freedman其他文献
JANE E Freedman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JANE E Freedman', 18)}}的其他基金
Circulating Proteomics to Phenotype the Development and Reversal of Myocardial Remodeling in Aortic Stenosis
循环蛋白质组学对主动脉瓣狭窄心肌重塑的发展和逆转进行表型分析
- 批准号:
10844786 - 财政年份:2023
- 资助金额:
$ 0.32万 - 项目类别:
Circulating Proteomics to Phenotype the Development and Reversal of Myocardial Remodeling in Aortic Stenosis
循环蛋白质组学对主动脉瓣狭窄心肌重塑的发展和逆转进行表型分析
- 批准号:
10658707 - 财政年份:2023
- 资助金额:
$ 0.32万 - 项目类别:
Long Non-coding RNA as Mediators of Metabolic Disease
长非编码 RNA 作为代谢疾病的介质
- 批准号:
10338074 - 财政年份:2021
- 资助金额:
$ 0.32万 - 项目类别:
Long Non-coding RNA as Mediators of Metabolic Disease
长非编码 RNA 作为代谢疾病的介质
- 批准号:
10496586 - 财政年份:2021
- 资助金额:
$ 0.32万 - 项目类别:
The Effect of Behavioral Weight Loss on Circulating Extracellular RNA
行为减肥对循环细胞外 RNA 的影响
- 批准号:
10041786 - 财政年份:2020
- 资助金额:
$ 0.32万 - 项目类别:
Long Non-coding RNA as Mediators of Metabolic Disease
长非编码 RNA 作为代谢疾病的介质
- 批准号:
10083222 - 财政年份:2019
- 资助金额:
$ 0.32万 - 项目类别:
Racial and Ethnic Diversity in Human Extracellular RNA
人类细胞外 RNA 的种族和民族多样性
- 批准号:
8775017 - 财政年份:2014
- 资助金额:
$ 0.32万 - 项目类别:
Extracellular RNAs: Biomarkers for Cardiovascular Risk and Disease
细胞外 RNA:心血管风险和疾病的生物标志物
- 批准号:
8711589 - 财政年份:2013
- 资助金额:
$ 0.32万 - 项目类别:
Extracellular RNAs: Biomarkers for Cardiovascular Risk and Disease
细胞外 RNA:心血管风险和疾病的生物标志物
- 批准号:
9325089 - 财政年份:2013
- 资助金额:
$ 0.32万 - 项目类别:
Extracellular RNAs: Biomarkers for Cardiovascular Risk and Disease
细胞外 RNA:心血管风险和疾病的生物标志物
- 批准号:
9319351 - 财政年份:2013
- 资助金额:
$ 0.32万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 0.32万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 0.32万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 0.32万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 0.32万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 0.32万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 0.32万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 0.32万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 0.32万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 0.32万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 0.32万 - 项目类别: